New hair loss drug shows promise in early trial
NCT ID NCT07076706
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new medication called CG2001 for male pattern baldness in Chinese men aged 18 to 65. The goal was to see if it helps regrow hair and is safe to use. The trial involved 110 participants and measured changes in hair count after 24 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANDROGENETIC ALOPECIA (AGA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Tongren Hospital Affiliated to Capital Medical University
Beijing, Beijing Municipality, China
-
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
-
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China
-
Huashan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China
-
Jiangxi Provincial Dermatology Hospital
Nanchang, Jiangxi, China
-
Peking University People's Hospital
Beijing, China
-
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China
-
Xiangya Hospital of Central South University
Changsha, Hunan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can stem cell exosomes regrow hair? new trial investigates
- Scientists map hair loss at the cellular level to unlock new treatments
- Blood protein shots may boost hair growth in balding men
- New peptide serum takes on hair loss in head-to-head trial
- New pill could regrow hair in balding men
- One shot to stop balding? new trial tests fat injections against daily cream